Enclomiphene Citrate and Anesthesia: What You Need to Know Before Surgery

What Is Enclomiphene Citrate and Why Does It Matter Perioperatively?

Enclomiphene citrate is the trans-isomer of clomiphene, acting as a selective estrogen receptor antagonist at the hypothalamic-pituitary axis. By blocking estrogen negative feedback, it increases luteinizing hormone (LH) and follicle-stimulating hormone (FSH) output, which drives endogenous testicular testosterone synthesis. That mechanism distinguishes it from exogenous testosterone replacement therapy (TRT), but it does not make it pharmacologically inert in the surgical setting.

The SERM Class and Thrombosis Background

All SERMs carry a class-level signal for venous thromboembolism (VTE). The FDA label for clomiphene citrate, enclomiphene's parent compound, includes a thromboembolic warning. Tamoxifen, another SERM, carries a documented 2- to 3-fold increase in deep vein thrombosis (DVT) and pulmonary embolism risk in postoperative patients in the ATAC trial (N=9,366) [1]. Enclomiphene shares the same core SERM pharmacology, and by mechanism, the same theoretical coagulation concern applies, particularly when combined with surgical immobility and inflammatory cascade activation.

Endogenous Testosterone and Hemostasis

Raising endogenous testosterone through SERM-mediated LH stimulation can itself influence platelet aggregation and hematocrit. A 2023 study in the Journal of Clinical Endocrinology and Metabolism (JCEM) showed enclomiphene at 25 mg/day raised mean total testosterone from 232 ng/dL to 449 ng/dL over 12 weeks [2]. Elevated testosterone levels have been associated with increased erythropoiesis and, in some contexts, higher whole-blood viscosity, both factors an anesthesiologist should weigh before major surgery.

How Enclomiphene Is Metabolized and Where Anesthetic Drugs Intersect

CYP3A4 and CYP2C9 Pathways

Enclomiphene is primarily metabolized in the liver via CYP3A4 with secondary contribution from CYP2C9 [3]. Several agents used in the perioperative environment either inhibit or induce these enzymes, and that creates bidirectional exposure risk.

CYP3A4 inhibitors used perioperatively include fluconazole (antifungal prophylaxis in immunocompromised patients) and some macrolide antibiotics such as erythromycin. Co-administration may increase enclomiphene plasma area under the curve (AUC), potentially amplifying estrogenic and anti-estrogenic receptor effects.

CYP3A4 inducers include rifampin, carbamazepine, and phenytoin, drugs sometimes used in neurosurgical contexts or for seizure prophylaxis. These could lower enclomiphene exposure significantly, reducing its testosterone-raising effect.

Volatile Anesthetics and Hepatic Blood Flow

Isoflurane, desflurane, and sevoflurane all reduce hepatic blood flow in a dose-dependent manner [4]. Reduced hepatic perfusion during maintenance anesthesia may transiently impair CYP3A4 clearance, leading to accumulation of drugs with high hepatic extraction ratios. Enclomiphene's hepatic extraction ratio is not well characterized in primary literature, but its lipophilicity and CYP dependency make this a plausible concern for prolonged procedures.

Opioid Interactions

Opioids used perioperatively, particularly fentanyl and morphine, are also CYP3A4 substrates. The interaction is likely competitive rather than additive in most short procedures, but in patients on chronic high-dose opioids, CYP3A4 saturation before and after surgery is worth noting when counseling timing of enclomiphene resumption [5].

Thromboembolic Risk: The Most Clinically Significant Concern

Surgical patients already carry an elevated baseline VTE risk from immobility, tissue trauma, and coagulation factor release. Adding a SERM to this environment compounds the Virchow's triad.

SERM-Class VTE Data

In the NSABP P-1 chemoprevention trial (N=13,388), tamoxifen increased pulmonary embolism incidence by 3.01 per 1,000 patient-years compared to placebo [6]. Raloxifene data from the MORE trial (N=7,705) showed a relative risk of 3.1 for VTE versus placebo [7]. Enclomiphene-specific VTE data in the perioperative context do not yet exist as a primary trial endpoint. The analogy to these class-level data is imperfect but is the closest available evidence base for clinical decision-making.

What Surgeons and Anesthesiologists Typically Do

Most perioperative guidelines for SERMs reference the American Society of Regional Anesthesia (ASRA) and the Enhanced Recovery After Surgery (ERAS) Society's general principles on hormone-modifying drugs. Tamoxifen is commonly held for 4 to 6 weeks before elective major surgery at many academic centers, based on its longer half-life and more strong trial data. Because enclomiphene has a shorter half-life (approximately 10 hours), complete functional clearance may occur faster, but the decision to hold it must be individualized.

HealthRX Perioperative Decision Framework for Enclomiphene:

1. Minor ambulatory procedures (endoscopy, vasectomy, joint injection): Standard VTE prophylaxis applies. Holding enclomiphene is generally not required but should be discussed with the prescribing clinician.
2. Moderate procedures under general or spinal anesthesia lasting under 2 hours (hernia repair, laparoscopic cholecystectomy): Consider holding enclomiphene 5 to 7 days before surgery and restart after full ambulation is established.
3. Major surgery or procedures with anticipated prolonged immobility (orthopedic joint replacement, abdominal surgery, spinal fusion): Hold enclomiphene at least 10 to 14 days preoperatively. Use pharmacologic VTE prophylaxis per institutional protocol. Restart only after mobilization is confirmed.
4. Emergency surgery: Inform the anesthesiologist immediately. VTE risk stratification should drive prophylaxis intensity. Delay of enclomiphene restart is appropriate.

This framework is not a substitute for individual clinical judgment. It is based on SERM class pharmacology and general perioperative medicine principles.

Can You Drink Alcohol While Taking Enclomiphene Citrate?

Alcohol is not contraindicated with enclomiphene citrate on the FDA label for clomiphene or in available enclomiphene prescribing literature. However, several clinically relevant interactions warrant discussion.

Hepatic Metabolism Competition

Both ethanol and enclomiphene are processed by the liver. Acute alcohol ingestion competitively inhibits cytochrome P450 enzymes, transiently elevating plasma concentrations of co-administered hepatically metabolized compounds [8]. Chronic heavy alcohol use induces CYP2E1 while suppressing CYP3A4 expression, potentially reducing enclomiphene clearance over time.

Hypothalamic-Pituitary-Gonadal Axis Suppression

Alcohol suppresses LH pulsatility at the hypothalamic level and has direct Leydig cell toxicity at doses exceeding 3 to 4 standard drinks per day [9]. A patient using enclomiphene to raise endogenous testosterone could partially negate the drug's mechanism by regular heavy alcohol use. A 2019 review in Alcoholism: Clinical and Experimental Research documented testosterone reductions of 6.2% to 23% in men with chronic alcohol use disorder compared to controls [9].

Perioperative Alcohol Use

Alcohol use within 24 hours of general anesthesia complicates airway management, increases aspiration risk due to delayed gastric emptying, and may alter minimum alveolar concentration (MAC) requirements for volatile agents. The American Society of Anesthesiologists (ASA) fasting guidelines require at least 8 hours abstinence from alcohol-containing beverages before elective procedures [10].

The practical guidance: occasional moderate alcohol use (1 to 2 standard drinks) is unlikely to produce a clinically significant interaction with enclomiphene at standard doses. Avoid alcohol for at least 24 to 48 hours before any surgical procedure.

Disclosing Enclomiphene to Your Surgical and Anesthesia Team

Why Disclosure Matters

Telehealth-prescribed medications like enclomiphene are not always captured in hospital medication reconciliation workflows. A 2021 study in JAMA Surgery found that 53% of patients undergoing elective procedures failed to list at least one prescription or supplement at pre-admission screening [11]. Enclomiphene's hormonal activity and thromboembolic risk profile make omission potentially consequential.

What to Tell the Team

Bring the medication bottle or the HealthRX prescription summary to your pre-operative appointment. Tell the anesthesiologist:

• The drug name: enclomiphene citrate
• The dose: typically 12.5 mg or 25 mg once daily
• How long you have been taking it
• Whether you have any personal or family history of blood clots

The anesthesiologist will integrate this information into VTE prophylaxis planning, which may include adjusted heparin dosing, sequential compression devices, or early ambulation orders.

Medication Reconciliation and LH/FSH Monitoring

If enclomiphene is held preoperatively, testosterone and LH levels will decline within 5 to 7 days given the drug's short half-life [2]. For patients who required months to optimize their hormonal response, a brief perioperative hold should not cause permanent axis suppression. Restart with prescriber guidance once the surgical team clears the patient for full activity.

Other Drug Interactions Relevant to the Perioperative Setting

Anticoagulants

If your surgical team initiates pharmacologic VTE prophylaxis (e.g., enoxaparin 40 mg subcutaneous daily) perioperatively, there is no direct pharmacokinetic interaction with enclomiphene. The risk is additive at the clinical level: both agents influence coagulation dynamics, so monitoring for bruising or hematoma formation is appropriate.

NSAIDs and COX-2 Inhibitors

Celecoxib and other NSAIDs used for postoperative pain management are CYP2C9 substrates, sharing that metabolic pathway with enclomiphene [3]. Co-administration is generally safe at standard perioperative doses, but patients with hepatic impairment or those on high-dose NSAIDs for extended periods may benefit from a dose review.

Sedative-Hypnotics and Anxiolytics

Midazolam, a CYP3A4 substrate used for procedural sedation, may have mildly altered clearance if enclomiphene is co-administered. A 2017 pharmacokinetic review in the British Journal of Anaesthesia noted that CYP3A4 competition at therapeutic doses of two substrates typically produces less than 20% change in AUC for either drug, a clinically modest interaction [12]. Standard midazolam dosing titrated to clinical effect remains appropriate.

Hormonal Contraceptives and Hormone Therapy

Enclomiphene is not indicated for use in women, but if prescribed off-label or taken by a partner in a household, it should not be combined with estrogenic oral contraceptives. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism explicitly recommends against co-administration of SERMs with exogenous estrogens, as the receptor-level antagonism becomes unpredictable [13].

Special Populations and Perioperative Considerations

Patients With Prior VTE History

A prior DVT or pulmonary embolism places a patient in the high-risk category for perioperative thrombosis. For these patients, holding enclomiphene before any procedure involving general or neuraxial anesthesia is strongly advisable. The prescribing clinician, surgeon, and hematologist (if anticoagulated) should coordinate care.

Patients With Liver Disease

Child-Pugh B or C hepatic impairment significantly reduces CYP3A4 and CYP2C9 activity. Enclomiphene accumulation is more likely perioperatively in these patients, given the added hepatic stress of surgery and volatile anesthetics. The FDA's prescribing information for clomiphene contraindications includes hepatic dysfunction, and the same principle applies to enclomiphene [14].

Patients Over 60

Older patients have reduced CYP450 enzyme activity and slower drug clearance. A 68-year-old man taking 25 mg enclomiphene daily will have higher steady-state plasma concentrations than a 35-year-old at the same dose. Perioperative dose reduction or extended hold periods may be appropriate; this is a conversation for the prescribing clinician before any surgical date is scheduled.

What the Research Does Not Yet Tell Us

Enclomiphene-specific perioperative pharmacokinetic studies have not been published as of early 2025. The drug received FDA Breakthrough Therapy designation in 2015 for male secondary hypogonadism, but a New Drug Application (NDA) had not reached final approval as of the most recent FDA designation record [15]. Off-label use is widespread in men's health telehealth. That regulatory gap means anesthesiologists and surgeons are working from SERM class data and clomiphene precedent, not enclomiphene-specific trials.

Clinicians managing perioperative care for patients on enclomiphene should document their risk-benefit reasoning. The HealthRX medical team recommends noting in the chart that enclomiphene's perioperative VTE risk is extrapolated from SERM class literature and that individualized VTE prophylaxis was applied accordingly.